Bio:
Prof Lisa Horvath MBBS (hons1) FRACP PhD is the Director of Research and Chief Clinical Officer at the Chris O’Brien Lifehouse, Professor of Medical Oncology (Genitourinary cancer) at the University of Sydney and Head of Advanced Prostate Cancer Research/Faculty member at the Garvan Institute for Medical Research.
She is a clinician scientist, has an active clinical practice and is involved with a large number of clinical trials in prostate cancer in addition to phase I trial work. She has published >150 original research papers published in peer-reviewed journals in the last 20+ years across the fields of cancer biology, biomarkers and clinical trials.
Abstract:
There remain significant gaps in our ability to delay resistance and/or cure patients with metastatic hormone-sensitive prostate cancer (mHSPC). Dysregulated lipid metabolism has emerged as an important mechanism of AR pathway inhibitor (ARPI) resistance but has yet to be successfully targeted. Our team have established that elevated plasma sphingolipids, especially ceramides, are associated with an increased risk of metastasis in localised PC, early ARPI resistance in mHSPC, and both ARPI resistance and shorter overall survival in metastatic castration-resistant PC. These are actionable lipid signatures that are mediating upregulation of ceramide-driven S1P signalling resulting in enhanced PC cell viability and drug resistance. We are now developing a pipeline of therapeutic agents to use in trials of precision lipid metabolic therapy.
Host: Prof. Dr. Marianna Kruithof-de Julio, Cancer Therapy Resistance, Department for BioMedical Research, University of Bern.
The Special Seminar takes place from 2 pm – 3 pm.
